Selection of an early biomarker for vascular normalization using dynamic contrast-enhanced ultrasonography to predict outcomes of metastatic patients treated with bevacizumab

Selection of an early biomarker for vascular normalization using dynamic contrast-enhanced ultrasonography to predict outcomes of metastatic patients treated with bevacizumab. Lassau, N.; Coiffier, B.; Kind, M.; Vilgrain, V.; Lacroix, J.; Cuinet, M.; Taieb, S.; Aziza, R.; Sarran, A.; Labbe-Devilliers, C.; Gallix, B.; Lucidarme, O.; Ptak, Y.; Rocher, L.; Caquot, L. M.; Chagnon, S.; Marion, D.; Luciani, A.; Feutray, S.; Uzan-Augui, J.; Benatsou, B.; Bonastre, J.; Koscielny, S.. Ann Oncol. 2016; 1922-8: p.1922-8. doi:10.1093/annonc/mdw280 10.1093/annonc/mdw280. Epub 2016 Aug 8.

Article